| Catalog No. | HV375016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Chimeric |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | B- and T-lymphocyte attenuator, BTLA, CD272, B- and T-lymphocyte-associated protein |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | Q7Z6A9 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | JS004, Icatolimab, 2236068-83-8 |
|---|
| Background | Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
• The BTLA-HVEM axis restricts CAR T cell efficacy in cancer., PMID:38831106
• B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis., PMID:38676311
• BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion., PMID:38418488
• The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases., PMID:34163466
• Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans., PMID:32735845
• B and T lymphocyte attenuator regulates autophagy in mycobacterial infection via the AKT/mTOR signal pathway., PMID:33348294
• B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease., PMID:37655751
• The Function of B and T Lymphocyte Attenuator and Its Role in Transplantation., PMID:40040475
• B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer., PMID:40463377
• BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection., PMID:30984188
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
